DrugBiological
Ravulizumab clinical trials
Also written Ultomiris and ALXN1210.
- studies test it
- 35
- open now
- 8
- in phase 3
- 22
- first study started
- 2014
Keep track of what changes. Save the ravulizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2020 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
- Phase 3
- 22
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 4
Alexion Pharmaceuticals, Inc. (31) · Mayo Clinic (1) · Massachusetts General Hospital (1) · Brigham and Women's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1)
Often tested with
Tested in the same studies.
Eculizumab (2) · Satralizumab (1) · Inebilizumab (1) · Baricitinib (1)
Studies
Open first, then newest update. How each study uses ravulizumab is read from its arms, and is right about nine times in ten.
Testing it · 35
- Ravulizumab in Pregnancies Complicated by Severe Hypertensive DisordersRecruitingPhase 2Mayo ClinicNCT06333652Written as Ravulizumab
- Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)RecruitingPhase 3Alexion Pharmaceuticals, Inc.NCT07596784Written as Ravulizumab
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as Ravulizumab
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingPhase 3Alexion Pharmaceuticals, Inc.NCT07557420Written as Ravulizumab
- Study of Ravulizumab in Pediatric Participants With Primary IgANRecruitingPhase 3Alexion Pharmaceuticals, Inc.NCT07024563Written as Ravulizumab
- Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney TransplantationRecruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06830798Written as Ravulizumab
- Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUSRecruitingPhase 4Alexion Pharmaceuticals, Inc.NCT07308574Written as Ravulizumab
- A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabRecruitingPhase 4Alexion Pharmaceuticals, Inc.NCT07221838Written as Ravulizumab
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Active, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06291376Written as Ravulizumab
- ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKETerminatedPhase 3Alexion Pharmaceuticals, Inc.NCT05746559Written as Ravulizumab
- Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSDActive, not recruitingPhase 2/3Alexion Pharmaceuticals, Inc.NCT05346354Written as Ravulizumab
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04543591Written as Ravulizumab
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT06578949Written as Ravulizumab
- Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisActive, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT05644561Written as Ravulizumab
- Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)TerminatedPhase 2Alexion Pharmaceuticals, Inc.NCT04564339Written as Ravulizumab
- Study of Ravulizumab in Pediatric Participants With HSCT-TMACompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04557735Written as Ravulizumab
- An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSDCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04201262Written as Ravulizumab
- Ravulizumab Versus Placebo in Adult Participants With DermatomyositisTerminatedPhase 2/3Alexion Pharmaceuticals, Inc.NCT04999020Written as Ravulizumab
- Ravulizumab in Thrombotic Microangiopathy Associated With a TriggerTerminatedPhase 3Alexion Pharmaceuticals, Inc.NCT04743804Written as Ravulizumab
- Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT03748823Written as Ravulizumab
See all 35 studies that test ravulizumab →
Given in every arm · 6 — ravulizumab is usual care beside what is tested
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05133531Written as Ravulizumab
- A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedPhase 2BioCryst PharmaceuticalsNCT04702568Written as Ravulizumab
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 3Regeneron PharmaceuticalsNCT05131204Written as Ravulizumab
- ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT03056040Written as Ravulizumab
- ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT02946463Written as Ravulizumab
- Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult VolunteersCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05396742Written as Ravulizumab
As the comparator · 2 — what is tested is compared with ravulizumab
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTerminatedPhase 2BioCryst PharmaceuticalsNCT05116774Written as Ravulizumab
- Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentCompletedPhase 3Novartis PharmaceuticalsNCT04558918Written as Ravulizumab
Codes
What other systems call ravulizumab · ClinicalTrials.gg INT001020
- MeSH (NLM) C000629409ravulizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) C3VX249T6LRAVULIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2107301Confirmed FDA, Wikidata
- Wikidata Q55641547ravulizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C124657RavulizumabOne source FDA
- DrugBank DB11580One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629409 | ravulizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | C3VX249T6L | RAVULIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2107301 | — | Confirmed FDA, Wikidata |
| Wikidata | Q55641547 | ravulizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C124657 | Ravulizumab | One source FDA |
| DrugBank | DB11580 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.